HUKEYMB@EC2702A

Guojin Securities First Coverage of CanNova-B with a Buy Rating

Guo Jin Securities Reports Positive Outlook for Canomena-B

Conuma's Self-Developed New Drug Supicibai Monoclonal Antibody Injection (Kangyueda®) Included in the National Medical Insurance Catalogue

Pacific Securities Gives BUY Rating to CanNova-B

Significant Progress Achieved by Sanofi and Canonic's Dual Antibody Drugs in Respiratory and Autoimmune Diseases

Huatai Securities Maintains Buy Rating on CanNova Biologics Stock

Conuma-B's Self-Developed Drug CM512 I Phase Clinical Trial for Atopic Dermatitis Successful

Goldman Sachs Initiates Coverage of CanNova with Buy Rating

IL-4Rα Monoclonal Antibody Market Faces New Competitive Landscape

Knomia's Supiquibam Antibody Commercialization Boosts Profits and Initiates New Drug Phase III Trial

Lin gives a moderate buy recommendation for Keymed Biosciences

Supichibai Antibody Stands Out in Allergic Rhinitis Treatment

Huatai Securities Upgrades Kangerria's Target Price and Rating, Anticipates Strong Future Performance

CMBI Raises Target Price of Canona-B to HKD 78, Maintains Buy Rating

CLSA Raises Target Price on Canoda to HKD78

KEYMED BIO-B released FY2025 Q1 earnings on August 26 (BJT), actual revenue HKD 267.08 M, actual EPS HKD -0.1606

KEYMED BIO-B released FY2025 Semi-Annual Earnings on August 26 After-Market (BJT), with actual revenue of HKD 540.02 M and EPS of HKD -0.3248

KEYMED BIO-B released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue HKD 272.95 M, actual EPS HKD -0.1641

Canonic Biologics Announces Significant Increase in Mid-Year Revenue and Reduced Losses

KEYMED BIO-B to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

KO YO GROUP

GEOTECH HLDGS

CHINA INFO TECH

REDCO HEALTHY

AGTECH HOLDINGS

CH CITY INFRA

RMH HOLDINGS

MATRIX HOLDINGS

SOFTMEDX

PUTIAN COMM

02720

09899

08299

01773

03880

09959

00290

02629

02162

01440

RIDGE OUTDOOR(02720) fell 24.95%, with a trading turnover 35.0 Million HKD, and a year-to-date rose 132.8%. NETEASE MUSIC(09899) fell 9.62%, with a trading turnover 488.4 Million HKD, and a year-to-date fell 11.1%. GT GOLD(08299) fell 7.69%, with a trading turnover 53.7 Million HKD, and a year-to-date rose 17.6%.

Top Gainers & Losers

RIDGE OUTDOOR

NETEASE MUSIC

GT GOLD

TIANLI INT HLDG

Medtide Inc.

LINKLOGIS-W

GOFINTECH QUANT

MIRXES-B

KEYMED BIO-B

STAR SHINE HLDG

Top 10 HK Stock Losers (2.12)

Guojin Securities initiates coverage on KEYMED BIO-B with a "Buy" rating and a target price of HKD 83.29. It forecasts operating revenues of RMB 661 million, RMB 1.255 billion, and RMB 2.064 billion for 2025 to 2027, with annual growth rates of 54%, 90%, and 65%, respectively. Dupilumab, as the second IL-4R monoclonal antibody globally and the first in China, has been included in the national medical insurance catalog, expected to be implemented in early 2026, with sales expected to grow rapidly

AASTOCKS

Guotai Junan Securities initiates coverage on KEYMED BIO with a "Buy" rating and a target price of 83.29 yuan

Sinolink Securities analyst maintained a Buy rating on Keymed Biosciences, Inc. yesterday and set a price target of HK$83.29.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Keymed Biosciences, Inc. has an analyst consensus of Strong Buy, with a price target consensus of HK$88.61.

Tip Ranks

Keymed Biosciences, Inc. (2162) Receives a Buy from Sinolink Securities

KEYMED BIO announced that its independently developed new drug Kangyueda® (SIPUQIBAI monoclonal antibody injection) has been included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2025)," which will be officially implemented on January 1, 2026

Wallstreetcn

KEYMED BIO has been included in the National Basic Medical Insurance Drug List

Huatai Securities has maintained a Buy rating on Keymed Biosciences, Inc. (2162) with a price target of HK$91.08. Additionally, Goldman Sachs also issued a Buy rating on the company. However, TR | OpenAI reiterated a Hold rating on October 23.

Keymed Biosciences, Inc. (2162) Gets a Buy from Huatai Securities

Keymed Biosciences, Inc. has launched its first commercial product, stapokibart, approved in China for treating atopic dermatitis, chronic rhinosinusitis, and seasonal allergic rhinitis. This product is the first domestic IL-4Rα monoclonal antibody, offering a first-mover advantage. Analyst Ziyi Chen projects peak sales exceeding RMB 5 billion by 2035, highlighting its revenue potential and the opportunity for increased market penetration in biologic treatments, which could enhance the company's financial performance.

Keymed Biosciences’ Strategic Positioning and Stapokibart’s Market Potential in Biotech Sector

Goldman Sachs released a research report stating that it has initiated coverage on KEYMED BIO-B with a "Buy" rating and a target price of HKD 92.67. The firm indicated that the company's first commercialized product, Stapokibart, has been approved in mainland China for the indications of atopic dermatitis, chronic sinusitis, and seasonal allergic rhinitis. With Stapokibart's first-mover advantage in these areas, the firm believes the drug is expected to establish a valuation foundation for the company, with peak sales projected to exceed RMB 5 billion by 2035. Additionally, the firm anticipates that greater growth momentum will come from CM512, believing that this drug could become a preferred option for asthma and chronic obstructive pulmonary disease; it is expected that global sales of CM512 before and after the PoS stage could reach USD 3.3 billion and USD 694 million, respectively, by 2035

Zhitong

Goldman Sachs: Initiates coverage on KEYMED BIO-B with a Buy rating and a target price of HKD 92.67

KEYMED BIO-B's stock price rose over 7%, with an increase of 7.14% as of the time of writing, reported at HKD 64.55, with a trading volume of HKD 281 million. Goldman Sachs has given KEYMED BIO-B a "Buy" rating, with a target price of HKD 92.67, believing that its first commercialized product, Stapokibart, will lay the valuation foundation for the company, with peak sales expected to reach RMB 5 billion by 2035. The CM512 drug is also viewed positively, with global sales expected to reach USD 3.3 billion by 2035

Understanding the Market | KEYMED BIO-B rises over 7% as Goldman Sachs states that Siponimod is expected to lay the foundation for the company's valuation

01672

01873

Pharmaceutical stocks have continued to decline recently, with VIVA BIOTECH down 7.53%, ASCLETIS-B down 7.09%, and KEYMED BIO-B down 5.74%. Huaxin Securities pointed out that although the Sino-U.S. trade conflict may affect market confidence in the short term, Chinese innovative pharmaceutical companies still have strong competitiveness in the global market, and the next 2-3 years will remain an important investment direction. Cinda Securities believes that CXO companies play a key role in the global innovative pharmaceutical industry chain, and the industry's prosperity is recovering

ASCLETIS-B

VIVA BIOTECH

Understanding the Market | Pharmaceutical stocks have been declining for several consecutive days due to short-term external environmental changes, but institutions remain optimistic about the long-term industry development trend

Lin covers the Healthcare sector, focusing on stocks such as HUTCHMED, HUTCHMED (China) , and Innovent Biologics. According to TipRanks, Lin has an average return of 10.7% and a 50.00% success rate on recommended stocks. Keymed Biosciences, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of HK$93.50.

Morgan Stanley Sticks to Its Buy Rating for Keymed Biosciences, Inc. (2162)

KEYMED BIO-B's stock price rose more than 5% during the session, with an increase of 4.58% as of the time of publication, trading at HKD 75.4, with a transaction volume of HKD 87.53 million. The company's first dual-antibody drug, CM336, has initiated Phase III studies aimed at evaluating its efficacy and safety in patients with relapsed or refractory multiple myeloma. The primary endpoint of the study is progression-free survival (PFS)

Understanding the Market | KEYMED BIO-B rose over 5% during the session as its first dual-antibody drug CM336 initiated Phase III research

Certain Shares of Keymed Biosciences Inc. are under a Lock-Up Agreement that will end on 18-SEP-2025. The lock-up period lasts for 91 days, starting from 19-JUN-2025. According to the Placing and Subscription Agreement, the Top-up Vendor is restricted from selling or transferring these shares without prior consent from the Lead Bookrunner and Joint Bookrunners for 90 days following the Closing Date. This includes prohibitions on various forms of equity securities transactions and public announcements related to such transactions.

marketscreener

Certain Shares of Keymed Biosciences Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2025.

KEYMED BIO-B's stock price rose more than 10% in the morning, reaching HKD 75.4, with a transaction volume of HKD 171 million. The company released its performance for the first half of 2025, reporting revenue of 499 million yuan, a year-on-year increase of 812%. The core product, Siponimod, performed exceptionally well and is expected to have strong competitiveness in the autoimmune field, particularly in nasal indications. The company plans to participate in the 2025 medical insurance negotiations to enhance product accessibility, with significant potential in multiple early pipelines in the future

Understanding the Market | KEYMED BIO-B rose over 10% in the morning, with impressive commercialization results for Spiqi monoclonal antibody in the first half of the year and strong competitiveness in the AD field

HUKEYMB@EC2702A(23855.HK)

Top 10 HK Stock Losers (2.12)

Guotai Junan Securities initiates coverage on KEYMED BIO with a "Buy" rating and a target price of 83.29 yuan

Keymed Biosciences, Inc. (2162) Receives a Buy from Sinolink Securities

KEYMED BIO has been included in the National Basic Medical Insurance Drug List

Keymed Biosciences, Inc. (2162) Gets a Buy from Huatai Securities